Dysgeusia News and Research

RSS
Many hospitalized COVID-19 patients exhibit neurological symptoms, study finds

Many hospitalized COVID-19 patients exhibit neurological symptoms, study finds

Smell and taste changes last longer than other COVID-19 symptoms

Smell and taste changes last longer than other COVID-19 symptoms

Loss of taste in COVID-19 is highly variable by geographic region

Loss of taste in COVID-19 is highly variable by geographic region

A better understanding of SARS-CoV-2 in children

A better understanding of SARS-CoV-2 in children

Internet searches can help track the spread of COVID-19, says UofL researcher

Internet searches can help track the spread of COVID-19, says UofL researcher

Olfactory impairment linked with milder clinical course in COVID-19

Olfactory impairment linked with milder clinical course in COVID-19

COVID19 patients describe a loss of smell and taste

COVID19 patients describe a loss of smell and taste

FDA approves first therapy for symptomatic tenosynovial giant cell tumor

FDA approves first therapy for symptomatic tenosynovial giant cell tumor

FDA approves new treatment for AML patients

FDA approves new treatment for AML patients

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA